| Product Unit Size | Cost | Quantity | Stock |
|---|
ZCL-278 is an inhibitor of Cdc42 that exhibits anticancer activity. ZCL-278 inhibits microspike formation and disrupts GM130-docked Golgi structures. Additionally, this compound shows some anti-metastatic potential, inhibiting branching and actin-based motility and migration of prostate cancer cells in vitro.
| Cas No. | 587841-73-4 |
|---|---|
| Purity | ≥98% |
| Formula | C21H19BrClN5O4S2 |
| Formula Wt. | 584.89 |
| Chemical Name | 2-(4-bromo-2-chlorophenoxy)-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamothioyl]acetamide |
| IUPAC Name | 2-(4-bromo-2-chlorophenoxy)-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamothioyl]acetamide |
| Synonym | ZCL278 |
| Solubility | DMSO 100 mg/mL (170.97 mM) Water Insoluble Ethanol Insoluble |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Friesland A, Zhao Y, Chen YH, et al. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1261-6. PMID: 23284167.